These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21927531)

  • 1. The additive risk model for estimation of effect of haplotype match in BMT studies.
    Scheike TH; Martinussen T; Zhang MJ
    Scand Stat Theory Appl; 2011 Sep; 38(3):409-423. PubMed ID: 21927531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Aalen's additive and Cox proportional hazards models for breast cancer survival: analysis of population- based data from British Columbia, Canada.
    Abadi A; Saadat S; Yavari P; Bajdik C; Jalili P
    Asian Pac J Cancer Prev; 2011; 12(11):3113-6. PubMed ID: 22393999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A SAS macro for direct adjusted survival curves based on Aalen's additive model.
    Zhang X; Akcin H
    Comput Methods Programs Biomed; 2012 Oct; 108(1):310-7. PubMed ID: 22365671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types.
    Kaida K; Ikegame K; Inoue T; Maruyama S; Ishii S; Uchida N; Doki N; Eto T; Fukuda T; Katayama Y; Takada S; Kawakita T; Ichinohe T; Atsuta Y; Daimon T; Ogawa H
    Transplant Cell Ther; 2023 Apr; 29(4):273.e1-273.e9. PubMed ID: 36641032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unmanipulated haploidentical blood and marrow transplantation: where we are.
    Wu T; Lu DP
    Hong Kong Med J; 2009 Jun; 15(3 Suppl 3):27-30. PubMed ID: 19494393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation.
    McCurdy SR; Fuchs EJ
    Adv Hematol; 2015; 2015():431923. PubMed ID: 26713094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
    Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selecting the best haploidentical donor.
    McCurdy SR; Fuchs EJ
    Semin Hematol; 2016 Oct; 53(4):246-251. PubMed ID: 27788762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aalen's linear model for sampled risk set data: a large sample study.
    Zhang J; Borgan O
    Lifetime Data Anal; 1999 Dec; 5(4):351-69. PubMed ID: 10650742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution.
    Al-Qurashi F; Ayas M; Al Sharif F; Ibrahim E; Sahovic E; Al Mahr M; Chaudhri N; Al Mohareb F; Al Zahrani H; Al Jefri A; Al Omar H; Al Shanqeeti A; Seth P; Aslam M; El Solh H; Aljurf M
    Hematology; 2004 Apr; 9(2):123-9. PubMed ID: 15203867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Case for High Resolution Extended 6-Loci HLA Typing for Identifying Related Donors in the Indian Subcontinent.
    Agarwal RK; Kumari A; Sedai A; Parmar L; Dhanya R; Faulkner L
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1592-1596. PubMed ID: 28603069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.
    Brunstein CG; O'Donnell PV; Logan B; Dawson P; Costa L; Cutler C; Craig M; Hogan W; Horowitz MM; Horwitz ME; Karanes C; Magenau JM; Malone A; McCarty J; McGuirk JP; Morris LE; Rezvani AR; Salit R; Vasu S; Eapen M; Fuchs EJ;
    Transplant Cell Ther; 2022 Jul; 28(7):406.e1-406.e6. PubMed ID: 35390529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of additive hazards models for analyzing survival of breast cancer patients.
    Ataee Dizaji P; Vasheghani Farahani M; Sheikhaliyan A; Biglarian A
    J Res Med Sci; 2020; 25():99. PubMed ID: 33273944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data.
    Fallin D; Schork NJ
    Am J Hum Genet; 2000 Oct; 67(4):947-59. PubMed ID: 10954684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent U-shaped risk functions and Aalen's additive risk model.
    Martinussen T; Sørensen TI
    Biometrics; 1998 Sep; 54(3):989-1001. PubMed ID: 9750247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical related transplants and unrelated donor transplants with T cell addback.
    Veys PA; Meral A; Hassan A; Goulden N; Webb D; Davies G
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S42-4. PubMed ID: 9630324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
    Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The partly Aalen's model for recurrent event data with a dependent terminal event.
    Chen CM; Shen PS; Chuang YW
    Stat Med; 2016 Jan; 35(2):268-81. PubMed ID: 26265213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.